Nature Communications (Feb 2018)

Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

  • Xiao-Feng Li,
  • Hao-Long Dong,
  • Hong-Jiang Wang,
  • Xing-Yao Huang,
  • Ye-Feng Qiu,
  • Xue Ji,
  • Qing Ye,
  • Chunfeng Li,
  • Yang Liu,
  • Yong-Qiang Deng,
  • Tao Jiang,
  • Gong Cheng,
  • Fu-Chun Zhang,
  • Andrew D. Davidson,
  • Ya-Jun Song,
  • Pei-Yong Shi,
  • Cheng-Feng Qin

DOI
https://doi.org/10.1038/s41467-018-02975-w
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 11

Abstract

Read online

Given the recent Zika virus (ZIKV) epidemic, development of an effective vaccine is of high importance. Here, the authors use a licensed live-attenuated flavivirus vaccine backbone to develop a ZIKV vaccine and determine immunogenicity, safety and protection profiles in different animal models.